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Neuropeptide Y regulates numerous physiological processes via at least five different Y receptors, but the
specific roles of each receptor are still unclear. We previously demonstrated that Y2 receptor knockout results
in a lean phenotype, increased cancellous bone volume, and an increase in plasma pancreatic polypeptide (PP),
a ligand for Y4 receptors. PP-overexpressing mice are also known to have a lean phenotype. Deletion of the Y4
receptor also produced a lean phenotype and increased plasma PP levels. We therefore hypothesized that part
of the Y2 phenotype results from increased PP action on Y4 receptors and tested this in PP transgenic Y4/
and Y2/ Y4/ double knockout mice. Bone mass was not altered in Y4 knockout mice. Surprisingly, despite
significant hyperphagia, Y2/ Y4/ mice retained a markedly lean phenotype, with reduced body weight,
white adipose tissue mass, leptinemia, and insulinemia. Furthermore, bone volume was also increased three-
fold in Y2/ Y4/ mice, and this was associated with enhanced osteoblastic activity. These changes were
more pronounced than those observed in Y2/ mice, suggesting synergy between Y2 and Y4 receptor path-
ways. The lack of bone changes in PP transgenic mice suggests that PP alone is not responsible for the bone
mass increases but might play a major role in the lean phenotype. However, a synergistic interaction between
Y2 and Y4 pathways seems to regulate bone volume and adiposity and could have important implications for
possible interventions in obesity and for anabolic treatment of osteoporotic bone loss.
Neuropeptide Y (NPY) is an important regulator of numer-
ous physiological processes, such as food intake (9, 43), energy
homeostasis (22, 42), and growth and reproduction (2, 10).
These processes are mediated at least partially within the hy-
pothalamus, via five different Y receptors (Y1, Y2, Y4, Y5, and
y6). All of these receptors are expressed in the hypothalamus,
the brain stem, and peripheral tissues (12). Despite having
highly divergent primary structures, different Y receptors have
very similar pharmacological profiles, with few agonists and
antagonists that are selective for specific Y receptors and ac-
tive in vivo being presently available. Consequently, the spe-
cific roles of individual receptors and the mechanisms that
mediate the diverse physiological effects of NPY are not yet
clearly understood.
Recent studies with germ line and conditional Y receptor
knockout mouse models have begun to shed some light on the
functions of different Y receptors. We have shown that both
hypothalamus-specific and germ line Y2 receptor knockout
resulted in a lean phenotype in male mice (reduced body
weight and white adipose tissue [WAT] mass) (35) and a two-
fold increase in cancellous bone volume associated with accel-
erated bone formation (3). Consistent with the general inhib-
itory functions of NPY, it appears from these data that Y2
receptors directly or indirectly mediate the tonic stimulation of
adipocyte activity while also mediating tonic inhibition of os-
teoblastic bone-forming activity. The increased bone volume in
hypothalamic Y2/ mice was not associated with changes in
the concentrations in plasma of hormones that are known to
regulate bone physiology, notably leptin, thyroid hormones,
insulin-like growth factor 1 (IGF-1), corticosterone, or testos-
terone (3). The concentration of pancreatic polypeptide (PP)
in plasma was elevated threefold in these mice (35), however,
which could contribute to the regulation of energy homeostasis
and bone mass alone or in addition to Y2 deletion. PP is
released from F cells in the islets of Langerhans in response to
stimuli such as food ingestion, hypoglycemia, or neurogluco-
penia, predominantly via a vagal mechanism (16, 39). Y4, a
receptor for PP, has been found mainly in peripheral tissues
such as pancreas, intestine, colon, heart, and liver (5, 23).
However, high levels of Y4 receptors are also found in the
brain stem, including the nucleus of the solitary tract, the
dorsal vagal motor nucleus, and the area postrema, which is
considered to be accessible to circulating factors from the
periphery (21, 31). In addition to its direct action on the di-
gestive system, it has also been shown that circulating PP en-
hances digestive events such as gastric secretion, motility, and
emptying, through activation of a vagal mechanism via the
central Y4 receptor population (25, 27). Furthermore, PP re-
leased postprandially has also been shown to function as a
satiety signal, presumably again acting on specific Y4 receptors
in the brain stem (19). Our previous data indicate that Y2
receptors, specifically hypothalamic Y2 receptors, are involved
in the regulation of plasma levels of PP (35), perhaps by Y2-
induced inhibition of vagal efferent output (8). Further evi-
dence that Y2 receptor knockout may induce its effects on
energy homeostasis via increased plasma PP levels comes from
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the observation that PP-overexpressing mice have a lean phe-
notype similar to that of germ line Y2 receptor knockout mice
(45). In addition, germ line deletion of the Y4 receptor also
produced a lean phenotype accompanied by increased plasma
PP concentrations (37).
Whereas Y4 receptors in the brain stem can be accessed by
their high-affinity ligand PP, other central Y4 receptors which
are not accessible to circulating PP are likely to be activated by
the lower-affinity ligand NPY if its concentration reaches suf-
ficiently high levels. Such high hypothalamic NPY levels are
found, for example, in animal models of obesity such as the
leptin deficient ob/ob mouse, which interestingly also exhibits
increased bone mass (11). Moreover, elevated NPY levels are
also present in Y2/ mice. Thus, it is possible that the eleva-
tion in bone mass seen in these mice may occur as a result of
regulation via hypothalamic NPY, possibly through central Y4
receptors.
In order to delineate the different contributions of the Y2
and Y4 receptors to the regulation of energy homeostasis and
bone formation and to determine the potential involvement of
PP or central NPY in these effects, we generated Y2/ Y4/
double knockout mice and compared the effects on adiposity
and bone mass with reference to control, Y2/, and Y4/
mice. In addition, we investigated bone parameters in PP
transgenic mice.
MATERIALS AND METHODS
The research described here was conducted in compliance with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes and
with the New South Wales Animal Research Act, with the approval of the
Garvan/St. Vincent’s Animal Experimentation Ethics Committee.
Generation of germ line Y2/, Y4/, and Y2/ Y4/ double knockout
mice and PP transgenic mice. Germ line deletion of Y2 and Y4 receptor genes
was achieved as previously described (35, 37) by crossing conditional-knockout
floxed mice (Y2lox/lox or Y4lox/lox) with oocyte-specific Cre recombinase-express-
ing C57/BL6 mice (40). This results in the removal of the entire coding region of
the Y2 or Y4 gene. Y2/ Y4/ double knockout mice were obtained by
crossing Y2/ and Y4/ mice, and the lack of the genes was confirmed by
Southern blot analysis. Noninduced floxed Y2lox/lox animals were used as con-
trols. All mice generated were maintained on a mixed C57BL/6-129/SvJ back-
ground. PP transgenic and age-matched nontransgenic mice were generated as
previously described (45).
Measurement of food intake and body weight. Groups of 13 to 32 animals per
genotype originating from four different breeding pairs were group housed and
fed with standard chow. Body weight was monitored at the same time each week
from 4 weeks of age onwards. Food intake was measured over 7 days at 12 weeks
of age.
Tissue collection and analysis. All analyses were carried out with male mice,
which were injected with the fluorescent tetracycline compounds calcein and
demeclocycline (Sigma Chemical Co., St. Louis, Mo.), each at 20 mg/kg, at 10
and 3 days prior to collection, respectively. At 15 to 17 weeks of age, control,
Y2/, Y4/, and Y2/ Y4/ knockout mice were killed by cervical dislo-
cation at between 10.00 to 14.00 h for collection of trunk blood. Plasma was
separated and immediately frozen. The brain was removed and immediately
frozen on dry ice, and interscapular brown adipose tissue (BAT) and WAT
deposits (right inguinal, right epididymal, right retroperitoneal, and mesenteric)
were collected and weighed. The small intestine was removed, its length was
measured, and then it was flushed with isotonic saline, blotted, and weighed.
Both femora were excised and fixed in 4% paraformaldehyde (Merck, Darm-
stadt, Germany) at 4°C for 16 h.
Plasma insulin and leptin levels were measured by radioimmunoassay (Linco
Research, St. Louis, Mo.). Plasma PP was radioimmunoassayed by using guinea
pig anti-rat PP serum, 2nd Antibody Precipitating Systems (Linco Research), and
125I-rPP (Auspep, Parkville, Australia). Plasma corticosterone, testosterone, and
free T4 were measured by radioimmunoassay (ICN Biomedicals, Costa Mesa,
Calif.); plasma IGF-1 concentrations were radioimmunoassayed with a kit from
Bioclone Australia (Marrickville, Australia); and plasma glucose was determined
by colorimetry (Trace Scientific, Melbourne, Australia, and Sigma Diagnostics,
St. Louis, Mo.).
The right femora were bisected transversely at the midpoint of the shaft. Distal
halves were embedded undecalcified in methyl-methacrylate (APS Chemicals,
Sydney, Australia), and 5-m sagittal sections were analyzed (Bioquant; R&M
Biometrics Inc, Nashville, Tenn.) as described previously (3). Cortical parame-
ters were measured at the bisection point, using the proximal portion of the bone.
Cortical area was calculated by subtraction of the medullary area from the total
bone area, and cortical thickness was calculated by radius difference, assuming
circularity. Sections were stained for mineralized bone (28), and the cancellous
bone volume, trabecular thickness, and number were calculated (30). Osteoblast
parameters (osteoblast surface, osteoblast number, and osteoid surface) were
estimated by using von Kossa- and toluidine blue-stained sections, with miner-
alizing surface, mineral apposition rate, and bone formation rate estimated
following fluorescence microscopy (Leica, Heerbrugg, Switzerland) of unstained
sections (29). Osteoclast surface and osteoclast number were estimated from
sections stained for tartrate-resistant acid phosphatase activity as described pre-
viously (17).
In situ hybridization. Coronal slices (20 m) of frozen brains were cut and
thaw mounted on charged slides. For in situ hybridization, DNA oligonucleotides
complementary to mouse NPY (5-GAGGGT CAGTCCACACAGCCCCATT
CGCTTGTTACCTAGCAT-3), proopiomelanocortin (POMC) (5-TGGCTGC
TCTCCAGGCACCAGCTCCACACATCTATGGAGG-3), cocaine- and am-
phetamine-regulated transcript (CART) (5-TCCTTCTC GTGGGACGCATC
ATCCACGGCAGAGTAGATGTCCAGG-3), agouti-related protein (AgRP)
(5-AGCTTGCGGCAGTAGCAAAAGGCATTGAAGAAGCGGCAGTAGC
AC-3), corticotropin-releasing hormone (CRH) (5-CCGATAATCTCCATCA
GTTTCCTGTTGCTGTGAGCTTGCTGAGCT-3), thyrotropin-releasing
hormone (TRH) (5-AACCTTACTCCTCCAGAGGTTCCCTGACCCAGGC
TTCCAGTTGTG-3), and gonadotropin-releasing hormone (GnRH) (5-CAA
ACACACAGTCAGCAGTAGAATGCCGGCCATCAGTTTGAGGATC-3)
mRNAs were labeled with [35S]thio-dATP (Amersham, Buckinghamshire,
United Kingdom) by using terminal deoxynucleotidyltransferase (Roche, Mann-
heim, Germany). Matching sections from the same portion of the hypothalamus
(approximately 1.8 mm [for POMC and CART] to 1.9 mm [for NPY and
AgRP] from Bregma for arcuate neurons and approximately 0.8 mm from
Bregma for the paraventricular nucleus) of knockout and control mice were
assayed together, as described previously (14, 35). Hybridizations with the re-
spective sense oligonucleotides and in the presence of an excess of unlabeled
antisense oligonucleotide were included as controls in some experiments.
For evaluation of in situ hybridization, digitized images of the areas of interest
were acquired from photoemulsion-dipped and superficially counterstained
brain slices at a magnification of 200 with a digital camera (ProgRes 3008;
Zeiss, Heidelberg, Germany) mounted onto a Zeiss Axiophot microscope, as
previously described (36). Silver grain density was evaluated by an experimentally
blinded observer by outlining single neurons and measuring the total neuronal
area and the area covered by silver grains (black grains in bright-field image),
using NIH Image software (version 1.61; available free from the Research Ser-
vices Branch, National Institute of Mental Health [http://rsbweb.nih.gov/nih-
image/index.html]). The percentages of silver grain area compared to total area
calculated for single neurons were averaged. Data are given as percentage of
control silver grain density averaged from at least four sections (80 neurons) per
peptide per animal.
Statistical analyses. Results were assessed by factorial analysis of variance.
When there was a significant overall effect of Y2, Y4, or Y2 and Y4 deficiency,
or interaction effects, Fisher’s or Contrasts posthoc test was performed to iden-
tify differences, using StatView version 4.5 (Abacus Concepts Inc., Berkeley,
Calif.). For all statistical analyses, a P value of 0.05 was accepted as being
statistically significant.
RESULTS
Increased food intake and reduced adiposity in Y2/ Y4/
double knockout mice. In order to examine the effect on energy
balance of Y4 receptor activity alone or in the context of Y2
deletion, Y4/ and Y2/ Y4/ mice were compared to
control and Y2/ mice. The body weights of male Y2/ and
Y4/ animals were significantly reduced compared with those
of control animals (Fig. 1A). In Y2/ Y4/ double knockout
mice there was also a significant decrease in body weight com-
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pared with control mice, although the difference was less pro-
nounced than in Y2/ and Y4/ animals (Fig. 1A). The 24-h
food intake of Y2/ Y4/ double knockout mice was signif-
icantly increased compared to those of control, Y2/, and
Y4/ mice (Fig. 1B).
WAT mass, either as a percentage of body weight or as an
absolute weight, was slightly but significantly decreased in male
Y2/ and Y4/ mice compared with control mice (Fig. 2A
and B), with a greater reduction in WAT in Y2/ Y4/
double knockout mice compared to that in control mice (Fig.
2A and B). The decreased adiposity of Y2/ Y4/ double
knockout mice was associated with significant reductions in the
plasma leptin (Fig. 2C) and insulin (Fig. 2D) concentrations
compared with those in control mice, changes that did not
reach significance in either Y2/ or Y4/ mice. Plasma
glucose and corticosterone concentrations were not signifi-
cantly different among the four groups of mice studied, al-
though there was a nonsignificant trend to decreased cortico-
sterone levels in the knockout mice (Fig. 2E and F). Since
Y2/ Y4/ double knockout mice had significantly greater
food intake than wild-type mice yet were lighter and leaner
than controls, we investigated BAT for evidence of increased
metabolic rate. Whereas Y2 or Y4 receptor knockout in iso-
lation had no significant effect on BAT weight (Fig. 3), Y2/
Y4/ double knockout mice showed a marked reduction in
BAT weight, both relative (Fig. 3A) and absolute (Fig. 3B).
These changes in BAT in Y2/ Y4/ mice were not associ-
ated with alterations in the concentrations of free T4 in
plasma, which were 21.8 3.0 pM in Y2/ Y4/ mice versus
20.0  2.1 pM in wild-type mice (not significant; n  10 mice
per group). Similarly, there was no significant change in plasma
IGF-1 concentrations (214 30 mg/dl in Y2/ Y4/ mice [n
 9] versus 304  29 mg/dl in wild-type mice [n  19] [P 
0.1]) and no significant change in plasma testosterone levels
(21.7  9.3 nM in Y2/ Y4/ mice [n  19] versus 14.2 
3.9 nM in wild-type mice [n  17] [P  0.37]). Neither the
FIG. 1. Body weight (A) and food intake (B) of male Y2/,
Y4/, and Y2/ Y4/ double knockout mice compared to those of
controls. Data are means  standard errors of the means per group.
The number of mice is indicated in parentheses. *, P  0.05; **, P 
0.01; and ***, P 0.001 (versus control or the comparison indicated by
horizontal bars).
FIG. 2. Adiposity and plasma hormone and metabolite concentrations in male Y2/, Y4/, and Y2/ Y4/ double knockout mice
compared to those in controls. (A and B) Masses of the right inguinal, right epididymal, right retroperitoneal, and mesenteric WAT depots,
expressed as a percentage of body weight (BWT) (A) or as absolute WAT weight (B). (C to F) Concentrations of leptin (C), insulin (D), glucose
(E), and corticosterone (cortico) (F) in plasma. Data are means  standard errors of the means for the number of mice indicated in parentheses.
*, P  0.05; **, P  0.01; ***, P  0.001 (versus control or the comparison indicated by horizontal bars).
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relative weight (as a percentage of body weight) nor the abso-
lute weight of the small intestine was significantly altered by
double deletion of Y2 and Y4 receptors (data not shown).
There was no difference in the length of the small intestine
between Y2/ Y4/ and wild-type mice (data not shown).
Plasma PP levels, however, were significantly elevated over
control values in Y2/, Y4/, and Y2/ Y4/ double
knockout mice (Fig. 4).
Synergistic increase in cancellous bone volume and bone
formation in Y2/ Y4/ double knockout mice. As Y2 re-
ceptor deletion had previously been shown to have a profound
effect on bone volume and osteoblast activity, these parameters
were compared in Y2/, Y4/, and Y2/ Y4/ mice. The
cancellous bone volume was increased over control values in
Y2/ but not in Y4/ mice (Fig. 5 and 6A to C). Y2/
Y4/ double knockout mice exhibited a profound increase in
bone volume, exceeding the increase induced by Y2 receptor
deficiency alone (Fig. 5 and 6). Cancellous bone volume, tra-
becular number, and trabecular thickness were significantly
increased over control values in Y2/ but not Y4/ mice.
Moreover, Y2/ Y4/ double knockout mice showed even
greater increases over control mice in these parameters. The
increased bone volume of Y2/ Y4/ double knockout mice
was associated with a significant increase in bone turnover,
with osteoblast, osteoclast, and osteoid surfaces elevated as
much as 100% compared to those of control, Y2/, or Y4/
mice (Table 1). However, osteoblast and osteoclast numbers
were not different from those of controls in the double knock-
out mice, unlike the case for Y2/ mice, in which osteoclast
number was decreased, and Y4/ mice, in which osteoblast
number was decreased (Table 1). The osteoblastic bone for-
mation rate was significantly increased over control values in
Y2/ Y4/ double knockout mice, driven by an increase in
mineral apposition rate, with no change in mineralizing surface
(Table 2).
Whereas the Y2/ Y4/ double knockout increased the
volume and rate of formation of cancellous bone, these mice
showed significant reductions in the area and thickness of
cortical bone compared to control mice (Fig. 6D and E). This
change was associated with a reduction in the periosteal diam-
eter of the cortical shaft, with no change in the endosteal
diameter (data not shown). There was no effect of Y2 or Y4
single gene deletion on cortical area or cortical thickness (Fig.
6D and E).
PP overexpression does not alter bone volume or bone turn-
over. In order to investigate the effect of chronically elevated
plasma PP levels on bone homeostasis in animals with a com-
plete set of Y receptors, bone tissue from male PP transgenic
mice and age-matched control mice on the same genetic back-
ground was investigated (45). Neither cancellous bone volume
nor cortical area was different from control values in PP trans-
genic mice (data not shown). Bone turnover was also similar to
control values, with no differences in osteoblast and osteoclast
surface and number and osteoid surface values (data not
shown). These data suggest that an elevated PP level alone is
not capable of changing bone mass.
Altered expression of neuropeptides in the hypothalamus of
Y2/ Y4/ double knockout mice. As both Y2 and Y4 re-
ceptors are expressed in hypothalamic nuclei that are impor-
tant in the regulation of energy homeostasis and autonomic
output, we investigated the expression of several important
neurotransmitters in these areas in the different models. In
accordance with previous data, Y2 deficiency tended to in-
crease NPY and AgRP mRNA levels, while POMC and CART
mRNA levels in the arcuate nucleus were down-regulated
compared to those in control mice (35). Y4 deletion did not
significantly affect the expression of these neuropeptides in the
arcuate nucleus (Fig. 7, Table 3). Interestingly, Y2/ Y4/
animals displayed an even greater increase in NPY mRNA
levels than Y2/ mice, with significant increases in AgRP
mRNA and significant decreases in CART mRNA also ob-
served in the arcuate nucleus compared to control animals
(Fig. 7; Table 3). The decreased POMC mRNA levels seen in
Y2/ mice were normalized by the double knockout (Fig. 7;
Table 3). In the paraventricular nucleus, Y2 receptor knockout
resulted in strong decreases in the expression of both CRH and
TRH mRNAs, while Y4/ mice displayed increased TRH
and unchanged CRH mRNA levels. In Y2/ Y4/ animals
the decreased CRH mRNA levels seen in Y2/ mice were
unaffected by the additional deletion of the Y4 receptor. How-
ever, the strong reduction in TRH mRNA in Y2/ mice was
fully reversed, with TRH actually significantly increased in the
Y2/ Y4/ animals over control animals (Fig. 7; Table 3),
suggesting that different NPY pathways regulate these two
endocrine parameters. In addition to pure hypothalamic reg-
ulation of energy homeostasis and bone formation, we also
investigated functional changes in the gonadotropic axis, which
FIG. 3. Mass of BAT, expressed as a percentage of body weight
(BWT) (A) or as absolute weight (B). Data are means  standard
errors of the means for the number of mice indicated in parentheses.
*, P  0.05; **, P  0.01 (versus wild-type control or the comparison
indicated by horizontal bars).
FIG. 4. Plasma PP concentrations in Y2/, Y4/, and Y2/
Y4/ double knockout mice compared to those in controls. Data are
means  standard errors of the means for the number of mice indi-
cated in parentheses. *, P  0.05 versus control mice.
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also plays a role in bone homeostasis. The increased GnRH
levels observed in scattered forebrain neurons of Y4/ mice
were also observed in the Y2/ Y4/ double knockout mice
but not in Y2/ mice, further confirming that Y4 but not Y2
receptors are involved in the regulation of the gonadotropic
axis (Fig. 7; Table 3) (37).
DISCUSSION
This study shows that simultaneous deletion of Y2 and Y4
receptors results in striking reductions in adiposity, leptinemia,
and insulinemia and a marked threefold increase in cancellous
bone volume. These findings demonstrate synergy between Y2
and Y4 receptors in the regulation of adiposity, since individ-
ual deletion of Y2 or Y4 receptors resulted in only slight
reductions in adiposity, with no significant effects on leptine-
mia or insulinemia. The double knockout thus reveals a level of
complexity in the regulation of Y receptor-mediated signals
that was not made apparent in previous single knockout mod-
els. Synergy was also evident in the bone mass increase, as Y2
but not Y4 receptor single gene knockout resulted in increased
bone mass, whereas double knockout of Y2 and Y4 receptors
enhanced this phenotype by a further 90%. The initial hypoth-
esis that elevated PP levels can act via Y4 receptors to promote
decreased adiposity and increased bone mass did not hold, as
the phenotypes seen in Y2 knockout mice were not prevented
by simultaneous deletion of Y4 receptors. Moreover, PP over-
expression in transgenic animals did not increase bone mass.
This is in keeping with the observations that leptin-deficient
ob/ob mice have a high bone mass (11) but low circulating
levels of PP (18). However, the possibility that the elevated
plasma PP levels in these knockout models (increased sever-
alfold in all mutants) may influence energy homeostasis (45)
and insulin effects (15) by activating other Y receptors with
lower but still significant affinity for PP must be considered.
The Y2/ Y4/ double knockout mice will provide a useful
model in the investigation of these pathways.
It is of particular interest that double knockout of Y2 and Y4
receptors resulted in such profound decreases in adiposity,
leptinemia, and insulinemia, because no single Y receptor de-
letion alone has resulted in such an obvious lean phenotype on
an already lean background. As action of NPY in the hypo-
thalamus causes increases in body weight, fat mass (42), lep-
tinemia (4), and insulinemia (1, 38, 46), it was expected that
knockout of the Y receptors for NPY would induce opposite
effects. However, this has not been the case with germ line
FIG. 5. Sagittal micrographs of distal femoral metaphyses of Y2/ Y4/ double knockout mice (D) compared to those of control (A), Y2/
(B), or Y4/ (C) male mice. The micrographs show darkly stained bone tissue and are representative of the respective groups. Bar, 1 mm.
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knockout of individual Y receptors, with reports describing
modest decreases in such parameters in Y2 and Y4 receptor
knockout mice (35, 37), no change in these parameters in
young Y5 receptor knockout mice (24), or counterintuitive
increases in these parameters consistent with positive energy
balance in Y1 receptor knockout mice (20, 32). The latter
observations lent support to the hypothesis that if Y receptors
do mediate the NPY-induced obesity syndrome, then there
must be considerable redundancy and/or compensation among
the receptor types or by other regulators of energy balance that
would obscure the consequences of single Y receptor deletion.
Our present data clearly reveal a less flexible system than was
initially postulated. The synergy between Y2 and Y4 receptors
in the regulation of adiposity demonstrates a lack of compen-
sation for the roles of these receptors by other regulators of
energy balance when both Y2 and Y4 receptors are missing.
The lack of compensation by other mechanisms is also partic-
ularly evident in the increased cancellous bone volume of
Y2/ Y4/ mice compared to mice with either Y2/ or
Y4/ single deletion.
Interestingly, food intake was significantly increased in
Y2/ Y4/ mice over control, Y2/, and Y4/ values. A
mechanism for this strong increase in food intake may involve
a lack of feedback inhibition from postprandially released fac-
tors such as PYY(3-36) and PP, each of which have been
shown to reduce food intake in humans and rodents by acting
on central Y2 and possibly Y4 receptors (6). Failure of these
inhibitory pathways due to the lack of both Y2 and Y4 recep-
tors might leave unchecked the orexigenic actions of NPY, the
expression of which was increased in the hypothalamus of
Y2/ Y4/ mice. NPY action in the hypothalamus through
Y receptors other than Y2 or Y4 may thereby also contribute
to the large increase in food consumption in the double knock-
out animals.
Importantly, however, this increase in food consumption was
accompanied by decreased adiposity in Y2/ Y4/ mice,
indicating a distinct mechanism that decreased fuel efficiency
in the double knockout animals. This mechanism does not
appear to involve increased physical activity, since the activity
of double knockout mice in a plus maze was not significantly
different from that of controls (data not shown). Although the
length and weight of the small intestine was not different in
FIG. 6. Effect of Y2/ Y4/ double knockout on bone morphology compared with no knockout, Y2/ knockout, or Y4/ knockout in male
mice. Trabecular bone volume (A), trabecular number (B), trabecular thickness (C), cortical area (D), and cortical thickness (E) were determined.
Data are means  standard deviations for 6 to 14 mice per group. *, P  0.05 versus control mice.
TABLE 1. Histomorphometric analysis of bone cells in distal femoral metaphysis in Y receptor knockout micea
Mice Osteoblastsurface (% OS)
Osteoblast no.
(/mm of OS)
Osteoid surface
(% BS)
Osteoclast
surface (% BS)
Osteoclast no.
(/mm)
Control 10.4  4.1 9.5  2.5 12.7  5.8 8.0  2.3 4.2  1.2
Y2/ 7.9  2.7 7.3  2.7 11.1  4.4 6.4  1.9 2.9  0.6*
Y4/ 10.1  3.7 5.0  1.5* 12.0  4.6 9.4  2.9 4.5  1.7
Y2/ Y4/ 18.6  5.9* 10.8  3.4 23.2  8.1* 14.1  5.8* 4.1  1.1
a Data are means  standard deviations for 6 to 14 mice per group. *, P  0.05 versus control. OS, osteoid surface; BS, bone surface.
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Y2/ Y4/ and wild-type mice, the possibility that decreased
intestinal absorption of nutrients contributed to the lean phe-
notype despite hyperphagia in the double knockout mice can-
not be excluded. BAT weight was significantly decreased in
Y2/ Y4/ mice, suggesting increased thermogenic activity
and combustion of the fat deposits within this tissue. These
data collectively suggest that increased metabolic rate, possibly
via enhanced thermogenesis in BAT, contributed to the de-
creased fuel efficiency of double knockout mice.
Increases in metabolic rate in small mammals can be
brought on by increases in sympathetic tonus and/or increases
in T3 concentration within the BAT. Indeed, thyroid hormones
and sympathetic neurotransmitters act in a coordinate fashion
to increase facultative thermogenesis (33, 41). Y2/ Y4/
double knockout mice did not show any change in concentra-
tions in plasma of free T4, a marker of thyrometabolic status
established by the hypothalamo-pituitary-thyrotropic axis (34).
However, this does not exclude the possibility that there may
have been increased production of metabolically active T3
within BAT by local activity of type II iodothyronine 5 deio-
dinase (41). Indeed, TRH expression was significantly in-
creased in the paraventricular nucleus of the hypothalamus in
Y2/ Y4/ mice.
The mRNA expression of hypothalamic neuropeptides that
are important in the regulation of energy homeostasis is
strongly altered in Y2/ knockout mice (35); however, with
the exception of slightly elevated TRH mRNA levels, these are
unaffected in Y4/ mice (37). In Y2/ Y4/ mice, the
expression of the orexigenic NPY and AgRP peptides in-
creased and the expression of the anorexic CART peptide
decreased, following the trends observed in the Y2/ mice.
Thus, the orexigenic stimulus associated with this set of
changes in NPY, AgRP, and CART expression levels is con-
sistent with the increase in food intake in Y2/ Y4/ double
knockout mutant mice. These mice, however, unlike Y2/
mice with intact Y4-mediated satiety signaling pathways, lack
both feedback inhibition by PYY(3-36) and PP, which may also
contribute to their hyperphagia, as discussed above. The
strongly reduced expression of CRH mRNA in the paraven-
tricular nucleus of Y2/ was not influenced by Y4 receptor
deletion, suggesting a purely Y2-mediated inhibitory effect on
this pathway. On the other hand, POMC and TRH mRNA
expression patterns in the double knockout mice exhibited
changes opposite to the Y2/ patterns, with Y4 receptor
deletion on the Y2/ background restoring POMC levels to
normal. More interestingly, not only did Y4 knockout abolish
a Y2/-associated reduction in TRH mRNA levels, Y4 dele-
tion actually increased the TRH mRNA signal in the double
knockout mice to levels significantly greater than those in con-
trol mice. NPY is known to inhibit the hypothalamo-pituitary-
thyrotropic axis by inhibition of TRH expression in the para-
ventricular nucleus (13), but the Y receptor type responsible
for this effect is not known. This observed pattern of TRH
FIG. 7. Effect of Y2/ Y4/ double knockout on CRH and TRH
mRNA levels in neurons of the paraventricular nucleus (upper pan-
els); on NPY, AgRP, POMC, and CART mRNA levels in the arcuate
nucleus (middle panels); and on GnRH mRNA levels in forebrain
neurons (lower panels) in male mice. High-power bright-field pho-
tomicrographs of dipped sections obtained from control and Y2/
Y4/ double knockout mice after in situ hybridization for the respec-
tive mRNA are shown. Bar, 100 m. The paraventricular nucleus is
depicted at about 0.8 mm and the arcuate nucleus is depicted at
about 1.8 to 1.9 mm from Bregma as low-magnification film auto-
radiographs for TRH and CART.
TABLE 2. Osteoblastic bone formation in Y2/ Y4/
double knockout micea
Mice Mineralizingsurface (%, BS)
Mineral apposition
rate (m/day)
Bone, formation
rate (m2/m/day)
Control 38.4  12.7 1.1  0.2 0.41  0.1
Y2/ Y4/ 39.6  7.2 1.4  0.2* 0.58  0.2*
a Data are means standard deviations for 9 to 14 mice per group. *, P 0.05
versus control. BS, bone surface.
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expression in our knockout models suggests that the elevated
NPY expression observed in Y2/ mice inhibited TRH ex-
pression via Y4 receptors, thereby implicating Y4 receptors in
the regulation of the thyrotropic axis. This observation also
indicates that elevated NPY levels in the Y2/ mice have the
potential to act on other Y receptors and thereby indirectly
modulate additional pathways such as the central regulation of
bone mass.
Coordinate deletion of the Y2 and Y4 receptors resulted in
a profound increase in cancellous bone volume associated with
marked increases in trabecular thickness and number, with
these anabolic changes enhanced compared to the Y2 knock-
out mouse phenotype. This increase in bone volume occurred
as a result of elevated bone formation, with an increased min-
eral apposition rate consistent with more active osteoblasts.
We previously demonstrated that selective deletion of hypo-
thalamic Y2 receptors alone released tonic inhibition of bone
formation by a mechanism independent of classic hormonal
mediators of bone homeostasis. Based on the present study,
plasma PP, which is strongly elevated in Y2/ mice, can now
be ruled out as the sole causative agent in the Y2/ bone
phenotype, as PP overexpression is not by itself capable of
stimulating bone formation. Moreover, as in Y2/ mice,
Y2/ Y4/ double knockout did not produce significant
changes in plasma corticosterone, free T4, IGF-1, or testoster-
one concentrations that would be expected to explain the in-
creased bone mass phenotype of these mice. However it must
be noted that the trend to reduced plasma IGF-1 levels in
Y2/ Y4/ mice and the pattern of change in bone mor-
phology in these animals is consistent with the observed effects
in bone of reduced activity of the growth hormone–IGF-1 axis
(7, 26).
Neuronal mechanisms of bone regulation may contribute to
the bone phenotype of Y2/ Y4/ mice, as recently de-
scribed (44). Since leptin inhibits bone formation (11) via cen-
tral activation of sympathetic nervous output to bone tissue
(44), the reduced leptinemia of Y2/ Y4/ double knockout
mice may contribute to their increased rate of bone formation
by abolishing hypothalamic NPY signaling through these Y
receptors, thus reducing sympathetic nervous activity and
thereby releasing 	-adrenergic inhibition of osteoblasts (44).
Importantly, Y2 and Y4 receptors are localized not only in the
hypothalamus but also in areas of the brain stem where they
have modulatory effects on sympathetic outflow (31). As the
selective deletion of hypothalamic Y2 receptors alone is suffi-
cient to significantly increase bone formation, double knockout
of these receptors might further reduce sympathetic outflow by
direct effects within the brain stem, thereby increasing bone
formation to an even greater extent.
In conclusion, these results demonstrate that Y2 and Y4
receptors act in a synergistic manner in the regulation of adi-
posity and bone volume. Deletion of both receptors in Y2/
Y4/ double knockout mice results in greater reductions in
adiposity and greater increases in cancellous bone volume than
in mice with deficiency of either the Y2 or Y4 receptor alone.
Of particular importance in the Y2/ Y4/ bone phenotype
is the increase in trabecular number, which represents a degree
of anabolic activity not achieved with any current osteoporosis
therapies. These findings have important implications for in-
tervention in obesity and for effective anabolic treatment of
even severe osteoporotic bone loss.
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